Kezar Life Sciences, Inc. (KZR): restructuring charge — Kezar Life Sciences cuts 70% of workforce (~31 employees) as part of strategic review

Kezar Life Sciences, Inc.

Workforce reduction of ~31 employees (approx. 70% of total staff) announced on Nov 6, 2025.
Estimated cash expenditures of ~$6.0M for severance and benefits, majority recognized in Q4 2025.
Restructuring linked to previously announced evaluation of strategic alternatives for the company.
Company may incur additional costs; will amend filing if material changes arise.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Kezar Life Sciences, Inc. announced a restructuring with charges of approximately $6.0 million affecting the Company (approximately 31 employees, or approximately 70%).

Type: restructuring
Charge: approximately $6.0 million
Affected area: the Company
Headcount: approximately 31 employees, or approximately 70%

Exact text from the filing

restructuring plan in connection with its previously announced evaluation of strategic alternatives. The Company estimates that it will incur cash expenditures of approximately $6.0 million, consisting primarily of one-time severance payments, benefits and other related costs. The Company expects to recognize the majority of such costs in the fourth quarter of 2025.

View on SEC.gov

Browse all restructurings & charges →

Kezar Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-25-050671

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.